MX2014012179A - Metodos para mejorar la resistencia a la fatiga musculo esqueletica. - Google Patents

Metodos para mejorar la resistencia a la fatiga musculo esqueletica.

Info

Publication number
MX2014012179A
MX2014012179A MX2014012179A MX2014012179A MX2014012179A MX 2014012179 A MX2014012179 A MX 2014012179A MX 2014012179 A MX2014012179 A MX 2014012179A MX 2014012179 A MX2014012179 A MX 2014012179A MX 2014012179 A MX2014012179 A MX 2014012179A
Authority
MX
Mexico
Prior art keywords
alkyl
xll
skeletal muscle
nrbrc
fatigue
Prior art date
Application number
MX2014012179A
Other languages
English (en)
Spanish (es)
Inventor
Fady Malik
Jeffrey R Jasper
Adam Kennedy
Darren Hwee
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MX2014012179A publication Critical patent/MX2014012179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2014012179A 2012-04-11 2013-04-11 Metodos para mejorar la resistencia a la fatiga musculo esqueletica. MX2014012179A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US201261735809P 2012-12-11 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Publications (1)

Publication Number Publication Date
MX2014012179A true MX2014012179A (es) 2015-07-14

Family

ID=49328282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012179A MX2014012179A (es) 2012-04-11 2013-04-11 Metodos para mejorar la resistencia a la fatiga musculo esqueletica.

Country Status (15)

Country Link
US (2) US20150250784A1 (enExample)
EP (1) EP2836590A4 (enExample)
JP (2) JP6352244B2 (enExample)
KR (1) KR102163931B1 (enExample)
CN (2) CN104395458A (enExample)
AU (3) AU2013245917A1 (enExample)
BR (1) BR112014025251B1 (enExample)
CA (1) CA2869675C (enExample)
EA (1) EA032480B1 (enExample)
HK (1) HK1206389A1 (enExample)
IL (2) IL234886A (enExample)
MX (1) MX2014012179A (enExample)
PH (1) PH12014502286A1 (enExample)
SG (2) SG10201704166RA (enExample)
WO (1) WO2013155262A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
LT3137622T (lt) * 2014-04-29 2022-04-25 Cytokinetics, Inc. Gyvybinio pajėgumo nykimo mažinimo būdai
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US9987279B2 (en) * 2014-09-09 2018-06-05 Astellas Pharma Inc. Pharmaceutical composition for prevention and/or treatment of urinary incontinence
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
US10906888B2 (en) 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
MX2022000947A (es) 2019-07-23 2022-04-26 Amorphical Ltd Carbonato de calcio amorfo para mejorar el rendimiento deportivo.
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
JP7825618B2 (ja) 2020-11-06 2026-03-06 サイトキネティックス， インコーポレイテッド 二環式１，４－ジアゼパノン及びその治療的使用
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CN101522681B (zh) * 2006-08-02 2012-10-03 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
CA2713864A1 (en) * 2008-02-04 2009-08-13 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2013151938A1 (en) * 2012-04-02 2013-10-10 Cytokinetics, Inc. Methods for improving diaphragm function

Also Published As

Publication number Publication date
KR102163931B1 (ko) 2020-10-12
SG11201406359TA (en) 2014-11-27
CN111840294A (zh) 2020-10-30
WO2013155262A2 (en) 2013-10-17
CA2869675A1 (en) 2013-10-17
BR112014025251B1 (pt) 2021-03-02
CA2869675C (en) 2022-06-14
PH12014502286B1 (en) 2014-12-15
EA201491666A1 (ru) 2015-03-31
JP6352244B2 (ja) 2018-07-04
KR20160046694A (ko) 2016-04-29
CN104395458A (zh) 2015-03-04
JP2015516392A (ja) 2015-06-11
JP6535727B2 (ja) 2019-06-26
JP2018048209A (ja) 2018-03-29
EP2836590A4 (en) 2016-04-13
WO2013155262A3 (en) 2013-12-27
US20190167676A1 (en) 2019-06-06
IL250473A0 (en) 2017-03-30
AU2019268177A1 (en) 2019-12-12
SG10201704166RA (en) 2017-06-29
HK1206389A1 (en) 2016-01-08
IL234886A (en) 2017-02-28
PH12014502286A1 (en) 2014-12-15
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
AU2013245917A1 (en) 2014-10-23
AU2018200930A1 (en) 2018-03-01
US20150250784A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
JP6535727B2 (ja) 骨格筋疲労に対する耐性を向上させるための方法
AU2017272286B2 (en) Methods for improving diaphragm function
US9186407B2 (en) Pharmaceutical compositions and their methods of use
JP2018509448A (ja) 組合せ医薬
AU2014368961A2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6419294B2 (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
TR201815342T4 (tr) Benzimidazol-prolin türevlerinin kullanımı.
JP2016528266A (ja) 位相変位睡眠障害を処置するためのＶ１ａアンタゴニスト
WO2011133858A2 (en) Compositions, methods of use, and methods of treatment
MX2007002460A (es) Metodos para tratar trastornos del humor utilizando derivados azabiciclicos de piridiloximetilo y benzisoxazol.
EA041725B1 (ru) Применение активатора тропонина скелетных мышц
BR112016014564B1 (pt) Compostos derivados de benzodiazepina, composição farmacêutica compreendendo ditos compostos e uso da mesma para o tratamento de deficiência cognitiva associada a um distúrbio do sistema nervoso central